Centessa Pharmaceuticals plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Centessa Pharmaceuticals plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.00M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.85M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 28, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($197.53M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($235.76M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($151.09M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($216.21M) | Mar 28, 2024 |
| FY2021 | Dec 31, 2021 | ($381.07M) | Mar 30, 2022 |
| FY2022 | Jan 29, 2021 | ($829.0K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.66M) | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | ($5.06M) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($207.69M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($201.06M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($171.28M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($212.26M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($374.08M) | Mar 30, 2023 |
| FY2022 | Jan 29, 2021 | ($783.0K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.44M) | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | ($5.05M) | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($193.82M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($142.06M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($160.34M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($200.55M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($135.11M) | Mar 30, 2023 |
| FY2022 | Jan 29, 2021 | ($1.05M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.63M) | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | ($5.83M) | Mar 30, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $371.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $34.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $169.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.14M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $186.0K | Mar 30, 2023 |
| FY2022 | Jan 29, 2021 | $0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $0 | Mar 30, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $687.50M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $576.80M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $360.25M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $444.31M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $629.64M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.72M | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.63M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $175.25M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $124.00M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $108.14M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $138.08M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $8.62M | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $526.86M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $401.55M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $236.24M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $336.17M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $491.55M | Mar 28, 2024 |
| FY2022 | Jan 29, 2021 | ($4.65M) | Mar 30, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.19B) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($988.70M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($752.95M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($601.86M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($385.65M) | Mar 30, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.30M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $383.22M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $128.03M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $393.64M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $595.08M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $7.23M | Mar 30, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.10M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $108.94M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 24, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 149.23M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 132.63M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 98.77M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 94.84M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 89.99M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |